2024 has been a remarkable year for the stock market, especially for two rising stars in the biotech space: Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT) . Both companies have seen their share prices more than double over the past year, thanks to groundbreaking advancements in their respective fields. According to top Wall Street analysts, the momentum might not stop there. BTIG analyst Justin Zelin has set a price target of $125 for Viking Therapeutics, projecting a staggering 166% upside for 2025. Meanwhile, Wells Fargo’s Mohit Bansal forecasts a 68% potential climb for Summit Therapeutics with a $30 price target. Let’s dive deeper into why these companies are catching Wall Street’s attention and explore the opportunities (and risks) they present. 1. Viking Therapeutics: A Weight Loss Contender Performance in 2024 Shares of Viking Therapeutics have soared by 157% from the end of 2023 through mid-December 2024. Much of this success is tied to the company’...